Cas9-cleavage sequences in minimal plasmids enhance non-viral genome targeting of CARs in primary human T cells

Ruirui Jing(First Affiliated Hospital Zhejiang University), Jie Sun(North Sichuan Medical University), Michel Sadelain(Columbia University Irving Medical Center), Yanting Duan, Peng Jiao(Zhejiang Lab), Xianhui Meng(Zhejiang University), Liling Qian(Center for Excellence in Brain Science and Intelligence Technology), Jiangqing Chen(First Affiliated Hospital Zhejiang University), Xun Zeng(First Affiliated Hospital Zhejiang University), Chun Zhou(Guangdong Pharmaceutical University), Weiwei Yin(Ministry of Education), Kai Shang(Zhejiang University), Wei Chen(Second Affiliated Hospital of Zhejiang University), Junwei Liu(Hong Kong Polytechnic University), Tao Huang(Zhejiang University), Xiaoyan Wu(Union Hospital), Jin Jin(Zhejiang University), Yanjie Huang(Westlake University), Xiaofei Gao(Whitehead Institute for Biomedical Research)
bioRxiv (Cold Spring Harbor Laboratory)
January 2, 2021
10.1101/2020.12.31.424920
Cited by 0

Related Papers

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Gene therapy comes of age
|Science|2018|1.4k
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
|Cell|2017|1.1k
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
|Nature|2019|659
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
|Cancer Discovery|2021|551